This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Two new studies involving more than 1 million U.S. veterans suggest that updated COVID-19 vaccines continue to provide meaningful protection against severe illness.
One study, published in Vaccine, found that the 2025–26 vaccine reduced the risk of emergency department visits by approximately 32% and the risk of hospitalization by roughly 44%. The second study, published in JAMA Network Open, found that the 2025–26 Moderna vaccine offered greater protection against medically attended COVID among older adults than Pfizer's vaccine.
In the first study, a team led by researchers from the Veterans Affairs (VA) Saint Louis Health Care System analyzed data from 931,943 veterans who received a seasonal flu vaccine from Sept. 21, 2025, to Jan. 31, 2026. Of those, 114,911 received a COVID vaccine on the same day, while 817,032 received only the flu vaccine.
Over the course of 180 days, COVID vaccination was associated with a 31.7% reduction in COVID-related emergency department (ED) visits and a 43.6% decrease in hospitalizations. That translates to approximately seven fewer ED visits and roughly three fewer hospitalizations per 10,000 people.
While the researchers note that the absolute risk reductions were modest, the findings "quantify the benefit of vaccination in a lower-incidence season and can inform shared clinical decision making and seasonal vaccine policy," they write.
S. veterans aged 65 years or older to assess whether 2025–26 vaccination was associated with a lower risk of COVID infection that required medical attention.
Source link







